Evidence map›Paper›PMID 34203212›Full record

ArticleInternational journal of molecular sciences2021

Evaluation of Firefly and

Maša Kenda, Jan Vegelj, Barbara Herlah, Andrej Perdih, Přemysl Mladěnka, Marija Sollner Dolenc

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Uncovering the role of sorbitol inBiochemistry and biophysics reports · 2024
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Maša KendaFaculty of Pharmacy, University of Ljubljana, Aškerčeva Cesta 7, 1000 Ljubljana, Slovenia.
Jan VegeljFaculty of Pharmacy, University of Ljubljana, Aškerčeva Cesta 7, 1000 Ljubljana, Slovenia.
Barbara HerlahFaculty of Pharmacy, University of Ljubljana, Aškerčeva Cesta 7, 1000 Ljubljana, Slovenia.
Andrej PerdihFaculty of Pharmacy, University of Ljubljana, Aškerčeva Cesta 7, 1000 Ljubljana, Slovenia.ORCID 0000-0002-6645-9231
Přemysl MladěnkaFaculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.ORCID 0000-0002-6076-6900
Marija Sollner DolencFaculty of Pharmacy, University of Ljubljana, Aškerčeva Cesta 7, 1000 Ljubljana, Slovenia.ORCID 0000-0002-0560-3762
University of Ljubljana · SICharles University · CZ

Funding

European Food Safety Authority CZ.02.1.01/0.0/0.0/16_019/0000841Javna Agencija za Raziskovalno Dejavnost RS P1-0208, P1-0012
6 · The paper itself

Abstract

Firefly luciferase is susceptible to inhibition and stabilization by compounds under investigation for biological activity and toxicity. This can lead to false-positive results in in vitro cell-based assays. However, firefly luciferase remains one of the most commonly used reporter genes. Here, we evaluated isoflavonoids for inhibition of firefly luciferase. These natural compounds are often studied using luciferase reporter-gene assays. We used a quantitative structure-activity relationship (QSAR) model to compare the results of in silico predictions with a newly developed in vitro assay that enables concomitant detection of inhibition of firefly and

Indexed as

AnimalsFirefliesGenes, ReporterIsoflavonesLuciferases, RenillaProtein Structure, SecondaryIsoflavonesLuciferases, Renillaalternative methodsfirefly luciferaseinhibitionisoflavonoidsmolecular dockingOECD test guidelinesquantitative structure–activity relationshipsRenilla luciferasereporter-gene assay

Identifiers

PMID34203212
PMCPMC8268740
OpenAlexW3177168998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.